29 Results for "

C3b

" in MedChemExpress (MCE) Product Catalog:
Products (29)

29 Results for "C3b" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P3252A
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Pegcetacoplan acetate is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acetate acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD) [3] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99905
CAS No.: 2375661-82-6
Synonyms: IBI302

Target:  

VEGFR

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
loading...
    loading...
Cat. No.: HY-NP004
Synonyms: CVF
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) [3].
loading...
    loading...
Cat. No.: HY-134222A
CAS No.: 16354-58-8
Purity:  ≥98.0%
Synonyms: N-Acetyl-L-serine
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification .
loading...
    loading...
Cat. No.: HY-178284
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Factor B-IN-7 (Compound (I)) is a selective Factor B inhibitor. Factor B-IN-7 inhibits Factor B-C3b interaction to suppress complement hyperactivation. Factor B-IN-7 is promising for research of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD) associated with complement-mediated diseases .
loading...
    loading...
Cat. No.: HY-177123
CAS No.: 2922808-66-8
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM. Refinicopan inhibits hemolysis of rabbit red blood cells. Refinicopan can be used to study diseases mediated by complement factor D .
loading...
    loading...
Cat. No.: HY-P991181

Research Areas:  

Cancer

VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .
loading...
    loading...
Cat. No.: HY-P990955
CAS No.: 2839652-75-2
Synonyms: ADX-097

Target:  

CD3 Complement System

Research Areas:  

Inflammation/Immunology

Ebribafusp alfa (ADX-097) comprising a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of factor H (fH1-5). Ebribafusp alfa binds C3d and related fragments, catalyzes AP convertase dissociation, acts as a factor I co-factor for C3b cleavage, and delivers fH1-5 moieties to C3d-deposited tissues for local complement inhibition without systemic blockade. Ebribafusp alfa reduces glomerular C3 deposition, proteinuria, urine albumin-creatinine ratios, and urine soluble C5b-9 levels, preserves podocyte foot-process architecture, inhibits skin complement activation, and localizes to UVB-damaged primate skin. Ebribafusp alfa can be used for the research of membranous nephropathy, bullous pemphigoid, discoid lupus erythematosus, C3 glomerulopathy, IgA nephropathy, and lupus nephritis .
loading...
    loading...
Cat. No.: HY-P83897
Synonyms: ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p

Host:  

Mouse

Application:  

WB, IHC-P, ICC/IF, FC, ELISA

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P83897A
Synonyms: ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p

Host:  

Mouse

Application:  

WB, IHC-P, ICC/IF, FC, ELISA

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P3252AS
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
loading...
    loading...
Cat. No.: HY-P704545
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P705136
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P991022
CAS No.: 2842046-67-5
Synonyms: NM8074

Target:  

Complement System

Research Areas:  

Endocrinology

Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy [3].
loading...
    loading...
Cat. No.: HY-RS01743
Research Areas:  

Others

C3 Human Pre-designed siRNA Set A contains three designed siRNAs for C3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P992456

Target:  

Complement System

SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
loading...
    loading...
Cat. No.: HY-P78247
Purity:  ≥ 95%, as determined by reducing SDS-PAGE or Bis-Tris PAGE.
Synonyms: Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P702819
Purity:  ≥ 95%, as determined by SDS-PAGE or Bis-Tris PAGE.
Synonyms: Complement C3; HSE-MSF; C3; CPAMD1; AHUS5; ARMD9; ASP; C3a; C3b; HEL-S-62p
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-181040
CAS No.: 3049710-19-9
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH) .
loading...
    loading...
Cat. No.: HY-P71552
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: C3Complement C3; Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2]
Species:  
Source:  
loading...
    loading...